Unusual 11 Mid-Day Movers 9/23: GBE, KERX, OPXA, AMFI Higher; FMAR, ATPG, FTBK, NCOC Lower

Grubb & Ellis (NYSE: GBE) <font>40% HIGHER;</font> continuing higher today on what appears to be a technical breakout. Since crossing over the $1 level, shares of GBE have jumped nearly 70% on very heavy volume.

Keryx Biopharmaceuticals (Nasdaq: KERX) <font>23.3% HIGHER;</font> announced results of the Open Label Extension trial of Zerenex (ferric citrate) for the treatment of elevated serum phosphorous levels, or hyperphosphatemia, in patients with end-stage renal disease on dialysis. The OLE trial, conducted in Taiwan, enrolled 29 of the 37 Taiwanese patients that had completed the randomized, multi-center, multi-national (United States and Taiwan) dose-ranging Phase 2 study.

Opexa